STARPHARMA.COM: Keyword Density Checker

Total words: 1728 | 2-word phrases: 463 | 3-word phrases: 498 | 4-word phrases: 506

PAGE INFO

Title	Try to keep the title under 60 characters (17 characters) Home - Starpharma
Description	Try to keep the meta description between 50 - 160 characters (203 characters) Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As an innovative Australian biopharmaceutical company, Starpharma is focused on...
Keywords	Meta keywords are not recommended anymore (203 characters) utilise,oncology,stage,clinical,multiple,includes,existing,solubility,performance,improve,therapeutics,develop,uses,pharmaceutical,advantageous,proprietary,based,developing,significant,australian,biopharmaceutical,company,focused,world,commercialising,sphry,therapeutic,otcqx,address,spl,global,healthcare,needs,boasts,strong,asx,partnerships,limited,intellectual,property,leader,medical,s,applications,innovative,rsquo,novel,ndash,portfolio,dendrimers,technology,dendrimer,products,starpharma
H1	No H1 tag on the page (0 characters)

ONE WORD PHRASES 261 Words

#	Keyword	Frequency	Density
1	and	19	7.28%
2	starpharma	14	5.36%
3	the	11	4.21%
4	is	10	3.83%
5	for	10	3.83%
6	of	10	3.83%
7	in	10	3.83%
8	a	9	3.45%
9	to	9	3.45%
10	starpharma’s	7	2.68%

TWO WORD PHRASES 463 Words

#	Keyword	Frequency	Density
1	business update	4	0.86%
2	starpharma business	3	0.65%
3	drug delivery	3	0.65%
4	announcement starpharma	3	0.65%
5	in the	3	0.65%
6	is registered	2	0.43%
7	any product	2	0.43%
8	viraleze™ is	2	0.43%
9	holdings limited	2	0.43%
10	starpharma holdings	2	0.43%
11	seeking information	2	0.43%
12	update asx	2	0.43%
13	dendrimer technology	2	0.43%
14	may 2024	2	0.43%
15	22 may	2	0.43%
16	update 22	2	0.43%
17	webinarstarpharma business	2	0.43%
18	investor webinarstarpharma	2	0.43%
19	registered in	2	0.43%
20	should be	2	0.43%

THREE WORD PHRASES 498 Words

#	Keyword	Frequency	Density
1	starpharma business update	3	0.60%
2	clinical trial results	2	0.40%
3	world leader in	2	0.40%
4	update 22 may	2	0.40%
5	trial results asx	2	0.40%
6	business update 22	2	0.40%
7	business update asx	2	0.40%
8	webinarstarpharma business update	2	0.40%
9	investor webinarstarpharma business	2	0.40%
10	is registered in	2	0.40%
11	starpharma holdings limited	2	0.40%
12	seeking information about	2	0.40%
13	positive final dep®	2	0.40%
14	final dep® irinotecan	2	0.40%
15	asx announcement starpharma	2	0.40%
16	phase 2 clinical	2	0.40%
17	2 clinical trial	2	0.40%
18	22 may 2024	2	0.40%
19	countries including in	1	0.20%
20	including in the	1	0.20%
21	in the uk	1	0.20%
22	the uk europe	1	0.20%
23	starpharma company products	1	0.20%
24	50 countries including	1	0.20%
25	than 50 countries	1	0.20%
26	bv is registered	1	0.20%
27	recurrent bv is	1	0.20%
28	of recurrent bv	1	0.20%
29	prevention of recurrent	1	0.20%
30	and prevention of	1	0.20%

FOUR WORD PHRASES 506 Words

#	Keyword	Frequency	Density
1	business update 22 may	2	0.40%
2	2 clinical trial results	2	0.40%
3	update 22 may 2024	2	0.40%
4	webinarstarpharma business update 22	2	0.40%
5	investor webinarstarpharma business update	2	0.40%
6	positive final dep® irinotecan	2	0.40%
7	phase 2 clinical trial	2	0.40%
8	clinical trial results asx	2	0.40%
9	available or approved in	1	0.20%
10	or approved in all	1	0.20%
11	oncology msd antibodydrug conjugates	1	0.20%
12	astrazeneca oncology msd antibodydrug	1	0.20%
13	including astrazeneca oncology msd	1	0.20%
14	companies including astrazeneca oncology	1	0.20%
15	approved in all countries	1	0.20%
16	chase sun antiinfectives and	1	0.20%
17	partnerships with international biopharmaceutical	1	0.20%
18	dep® partnerships with international	1	0.20%
19	multiple dep® partnerships with	1	0.20%
20	or may be available	1	0.20%
21	may be available under	1	0.20%
22	dep® programs starpharma has	1	0.20%
23	internal dep® programs starpharma	1	0.20%
24	company products and pipeline	1	0.20%
25	sun antiinfectives and other	1	0.20%
26	to starpharma’s internal dep®	1	0.20%
27	products that may not	1	0.20%
28	significant future milestones and	1	0.20%
29	generate significant future milestones	1	0.20%
30	to generate significant future	1	0.20%
31	potential to generate significant	1	0.20%
32	dep® programs have the	1	0.20%
33	partnered dep® programs have	1	0.20%
34	platform partnered dep® programs	1	0.20%
35	dep® platform partnered dep®	1	0.20%
36	starpharma’s dep® platform partnered	1	0.20%
37	about products that may	1	0.20%
38	that may not be	1	0.20%
39	antiinfectives and other worldleading	1	0.20%
40	applicability and optionality of	1	0.20%